CoverMyMeds

Patients don’t experience access as a process. They experience it as whether they can start therapy or not. In her latest feature with Pharmaceutical Commerce, Nicole Eckl, Vice President of Biopharma Commerical Solutions at CoverMyMeds, explores how everyday access disruptions can delay treatment for patients. For biopharma leaders, this is a moment to take a closer look at how access is designed and measured across the brand lifecycle. Read more at the link below.

Save the date: Join us for a conversation with Informa Connect on how Field Reimbursement programs evolve and deliver value across the brand lifecycle, from launch through LOE. As access challenges grow more complex, Field Reimbursement programs are being asked to do more than ever before. Today’s most effective programs aren’t just reactive, they’re designed to anticipate barriers, support specialized needs and deliver insights that shape brand strategy. If you're thinking about what’s next for access, this is one to mark on your calendar. ⬇️ 📅 June 25, 2026 ⏰ 11:00 AM ET Speakers: Kim Howard, Patrick Sadongo

Clinical expertise shouldn’t be slowed down by disconnected systems. Specialty care brings together providers, pharmacies, health plans and patient support, but when it doesn’t work as one, it takes time away from patients. In his latest conversation with Todd Eury of Pharmacy Podcast Network, Matt Hare, Vice President of Network Growth and Client Success, shares how AI and digital tools are helping bring specialty care into one connected workflow. With CoverMyMeds’ Specialty Access and Affordability Solutions, medical prior authorization, benefits investigation and patient enrollment come together, so teams spend less time navigating processes and more time with patients. Listen here: https://bit.ly/4uByw61.

As specialty therapies evolve, we have a clear path for what’s next: connected, consistent workflows. During our Innovation Roundtable, Miranda Delatore DNP, RN, NEA-BC, Vice President of Product at CoverMyMeds, shared why a seamless patient experience depends on an access infrastructure built to support patients end‑to‑end. Learn more: https://bit.ly/4uglWsa.

When access breaks down, patients wait. By simplifying high‑touch specialty workflows, CoverMyMeds helps care teams move work forward, so fewer delays stand between patients and the therapies they need. Learn more: https://bit.ly/48WHnqe.

Policy is shifting fast, from the IRA to drug pricing proposals, and patients can feel the impact first. During our Innovation Roundtable, Fauzea Hussain, Vice President of Public Policy at McKesson, shared how these decisions are reshaping what’s next for access, and what it will take to help patients start therapy sooner. Watch the full conversation: https://bit.ly/4uglWsa.

Getting on therapy shouldn’t mean more time waiting. Digital consent, automated enrollment, and affordability support, all connected in one workflow, help care teams move faster so patients can start sooner. Explore our enrollment services, redefined: https://bit.ly/48WHnqe.

Insights from #AXS26: Megan Wetzel, Vice President of Product, Access & Affordability, shares what’s next for biopharma, and how AI is being embedded directly into provider and care team workflows to help streamline access and reduce friction. Check out her interview with Pharmaceutical Commerce at the link below to learn more.

Check out the latest insights from CoverMyMeds' Miranda Delatore DNP, RN, NEA-BC in Pharmaceutical Commerce on how biopharma is adapting to a more complex access and affordability landscape. Her takeaway is clear: the next phase won’t be about adding more systems, but connecting what already exists across enrollment, prior auth and affordability so patients can start therapy sooner. Watch now at the link below.

Kim Howard, Senior Manager of Field Reimbursement Services at CoverMyMeds, recently spoke with Pharmaceutical Commerce about how real-world access challenges are driving field reimbursement metrics and team models to prioritize meaningful impact, flexibility, and outcomes. Read or watch her interview below.